60 Degrees Pharmaceuticals (NASDAQ:SXTP) Receives Neutral Rating from HC Wainwright

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “neutral” rating restated by equities research analysts at HC Wainwright in a report issued on Friday, Benzinga reports.

60 Degrees Pharmaceuticals Price Performance

NASDAQ SXTP opened at $1.38 on Friday. The company has a fifty day moving average price of $0.73 and a 200-day moving average price of $0.27. The firm has a market cap of $2.44 million, a price-to-earnings ratio of -1.33 and a beta of 4.61. 60 Degrees Pharmaceuticals has a 1 year low of $1.03 and a 1 year high of $18.36.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($4.23) EPS for the quarter, missing the consensus estimate of ($2.79) by ($1.44). The business had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.11 million. On average, research analysts anticipate that 60 Degrees Pharmaceuticals will post -5.43 EPS for the current fiscal year.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.